Hideyuki Akaza

Summary

Affiliation: University of Tokyo
Country: Japan

Publications

  1. ncbi Efficacy and safety of dutasteride on prostate cancer risk reduction in Asian men: the results from the REDUCE study
    Hideyuki Akaza
    Department of Urology, University of Tsukuba, Tsukuba, Japan
    Jpn J Clin Oncol 41:417-23. 2011
  2. ncbi Prostate cancer chemoprevention by soy isoflavones: role of intestinal bacteria as the "second human genome"
    Hideyuki Akaza
    Department of Strategic Investigation on Comprehensive Cancer Network, Research Center for Advanced Science and Technology, University of Tokyo, Tokyo, Japan
    Cancer Sci 103:969-75. 2012
  3. ncbi Fifth Joint Meeting of J-CaP and CaPSURE: advancing the global understanding of prostate cancer and its management
    Hideyuki Akaza
    Department of Strategic Investigation on Comprehensive Cancer Network, Research Center for Advanced Science and Technology, The University of Tokyo, Komaba, Meguro ku, Tokyo, Japan
    Jpn J Clin Oncol 42:226-36. 2012
  4. ncbi Combined immunotherapy with low-dose IL-2 plus IFN-alpha for metastatic renal cell carcinoma: survival benefit for selected patients with lung metastasis and serum sodium level
    Hideyuki Akaza
    Department of Strategic Investigation on Comprehensive Cancer Network, Research Center for Advanced Science and Technology, The University of Tokyo, 4 6 1 Komaba, Meguro ku, Tokyo 153 8904, Japan
    Jpn J Clin Oncol 41:1023-30. 2011
  5. ncbi Combined androgen blockade for prostate cancer: review of efficacy, safety and cost-effectiveness
    Hideyuki Akaza
    Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan
    Cancer Sci 102:51-6. 2011
  6. ncbi Aim of the working group on the Asian perspectives on cancer control: Asian perspective on prostate cancer prevention
    Hideyuki Akaza
    Department of Strategic Investigation on Comprehensive Cancer Network Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan
    Jpn J Clin Oncol 40:i2-6. 2010
  7. ncbi Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association
    Eiji Kikuchi
    Working Group of the Bladder Cancer Registration Committee of the Japanese Urological Association, Department of Urology, Keio University School of Medicine, Tokyo, Japan
    Int J Urol 16:279-86. 2009
  8. ncbi Treatment outcome of metastatic testicular cancer at a single institution in Japan, a country with low incidence of germ cell tumor
    Koji Kawai
    Department of Urology, Institute of Clinical Medicine, University of Tsukuba, Tsukuba City, Ibaraki 305, Japan
    Jpn J Clin Oncol 36:723-30. 2006
  9. ncbi Analysis of Intravesical Recurrence After Bladder-preserving Therapy for Muscle-invasive Bladder Cancer
    Mizuki Onozawa
    Department of Urology, Faculty of Medicine, University of Tsukuba, Tsukuba City, Japan
    Jpn J Clin Oncol 42:825-30. 2012
  10. ncbi Prediction of in vitro response to interferon-alpha in renal cell carcinoma cell lines
    Toru Shimazui
    Department of Urology, Institute of Clinical Medicine, Graduate School of Comprehensive Human Sciences, University of Tsukuba1 1 1 Tennodai, Tsukuba, Ibaraki, 305 8575, Japan
    Cancer Sci 98:529-34. 2007

Detail Information

Publications99

  1. ncbi Efficacy and safety of dutasteride on prostate cancer risk reduction in Asian men: the results from the REDUCE study
    Hideyuki Akaza
    Department of Urology, University of Tsukuba, Tsukuba, Japan
    Jpn J Clin Oncol 41:417-23. 2011
    ..A post hoc analysis of Asian men in the REDUCE study was conducted to investigate whether the outcomes were in line with those of the overall population...
  2. ncbi Prostate cancer chemoprevention by soy isoflavones: role of intestinal bacteria as the "second human genome"
    Hideyuki Akaza
    Department of Strategic Investigation on Comprehensive Cancer Network, Research Center for Advanced Science and Technology, University of Tokyo, Tokyo, Japan
    Cancer Sci 103:969-75. 2012
    ....
  3. ncbi Fifth Joint Meeting of J-CaP and CaPSURE: advancing the global understanding of prostate cancer and its management
    Hideyuki Akaza
    Department of Strategic Investigation on Comprehensive Cancer Network, Research Center for Advanced Science and Technology, The University of Tokyo, Komaba, Meguro ku, Tokyo, Japan
    Jpn J Clin Oncol 42:226-36. 2012
    ....
  4. ncbi Combined immunotherapy with low-dose IL-2 plus IFN-alpha for metastatic renal cell carcinoma: survival benefit for selected patients with lung metastasis and serum sodium level
    Hideyuki Akaza
    Department of Strategic Investigation on Comprehensive Cancer Network, Research Center for Advanced Science and Technology, The University of Tokyo, 4 6 1 Komaba, Meguro ku, Tokyo 153 8904, Japan
    Jpn J Clin Oncol 41:1023-30. 2011
    ..To clarify the survival benefit of immunotherapy for renal cell carcinoma patients with lung metastasis using low-dose interleukin-2 plus interferon-α, we examined survival outcomes and factors associated with prognosis...
  5. ncbi Combined androgen blockade for prostate cancer: review of efficacy, safety and cost-effectiveness
    Hideyuki Akaza
    Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan
    Cancer Sci 102:51-6. 2011
    ....
  6. ncbi Aim of the working group on the Asian perspectives on cancer control: Asian perspective on prostate cancer prevention
    Hideyuki Akaza
    Department of Strategic Investigation on Comprehensive Cancer Network Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan
    Jpn J Clin Oncol 40:i2-6. 2010
    ..Each Working Group spent a year preparing for this conference by analyzing contributing factor(s) and writing a consensus statement of a strategy for improving morbidity and mortality...
  7. ncbi Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association
    Eiji Kikuchi
    Working Group of the Bladder Cancer Registration Committee of the Japanese Urological Association, Department of Urology, Keio University School of Medicine, Tokyo, Japan
    Int J Urol 16:279-86. 2009
    ....
  8. ncbi Treatment outcome of metastatic testicular cancer at a single institution in Japan, a country with low incidence of germ cell tumor
    Koji Kawai
    Department of Urology, Institute of Clinical Medicine, University of Tsukuba, Tsukuba City, Ibaraki 305, Japan
    Jpn J Clin Oncol 36:723-30. 2006
    ..Objectives of the present investigation are to evaluate outcome of a single institution in Japan, and to identify prognostic factors for testicular cancer...
  9. ncbi Analysis of Intravesical Recurrence After Bladder-preserving Therapy for Muscle-invasive Bladder Cancer
    Mizuki Onozawa
    Department of Urology, Faculty of Medicine, University of Tsukuba, Tsukuba City, Japan
    Jpn J Clin Oncol 42:825-30. 2012
    ..The aim of the present study was to analyze the pattern of recurrences after bladder-preserving therapy for muscle-invasive bladder cancer...
  10. ncbi Prediction of in vitro response to interferon-alpha in renal cell carcinoma cell lines
    Toru Shimazui
    Department of Urology, Institute of Clinical Medicine, Graduate School of Comprehensive Human Sciences, University of Tsukuba1 1 1 Tennodai, Tsukuba, Ibaraki, 305 8575, Japan
    Cancer Sci 98:529-34. 2007
    ..Furthermore, the IFNalpha response to RCC might be modulated by regulation of the expression level of these molecules...
  11. ncbi Cancer death from non-muscle invasive bladder cancer: report of the Japanese Urological Association of data from the 1999-2001 registry in Japan
    Eijiro Okajima
    Working Group of the Bladder Cancer Registration Committee of the Japanese Urological Association Department of Urology, Nara City Hospital, Nara Department of Urology, National Cancer Center Hospital, Tokyo, Japan
    Int J Urol 17:905-12. 2010
    ..Our aim was to clarify the risk factors of cancer death in order to reduce mortality from T1 bladder cancer...
  12. ncbi Current status of endocrine therapy for prostate cancer in Japan analysis of primary androgen deprivation therapy on the basis of data collected by J-CaP
    Shiro Hinotsu
    Urology and Andrology, Graduate School of Comprehensive Human Sciences, University of Tsukuba, 1 1 1 Tennodai, Tsukuba City, Ibaraki Prefecture, 305 8575, Japan
    Jpn J Clin Oncol 37:775-81. 2007
    ....
  13. ncbi A case of metastatic testicular cancer complicated by tumour lysis syndrome and choriocarcinoma syndrome
    Koji Kawai
    Department of Urology, Institute of Clinical Medicine, University of Tsukuba Graduate School of Comprehensive Human Sciences, Tsukuba City, Ibaraki, Japan
    Jpn J Clin Oncol 36:665-7. 2006
    ..The urological oncologist should be aware of the potential complications TLS and choriocarcinoma syndrome in cases of rapidly progressive and high-volume choriocarcinoma...
  14. ncbi Radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation: Five-year results
    Yukio Homma
    Department of Urology, University of Tokyo, Tokyo, Japan
    Int J Urol 11:295-303. 2004
    ..The effects of preoperative androgen deprivation on the outcomes of prostate cancer patients who received radical prostatectomy and subsequent adjuvant endocrine therapy have not yet been fully evaluated...
  15. ncbi The 3rd Conference on Asian Trends in Prostate Cancer Hormone Therapy
    Hideyuki Akaza
    Department of Urology, Institute of Clinical Medicine, University of Tsukuba, Ibaraki 305 8576, Japan
    Gan To Kagaku Ryoho 31:1285-95. 2004
    ....
  16. ncbi Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival
    Hideyuki Akaza
    Department of Urology, Institute of Clinical Medicine, University of Tsukuba, Ibaraki, Japan
    Cancer 115:3437-45. 2009
    ..4 years indicated that CAB significantly (P<.001) prolonged the time to progression and the time to treatment failure. In the current report, survival data from a long-term follow-up (median, 5.2 years) were analyzed...
  17. ncbi Overall survival and updated results from a phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma
    Yoshihiko Tomita
    Department of Urology, Yamagata University School of Medicine, Yamagata, Japan
    Jpn J Clin Oncol 40:1166-72. 2010
    ..In a phase II, open-label, multicentre Japanese study, sunitinib demonstrated antitumour activity and acceptable tolerability in metastatic renal cell carcinoma patients. Final survival analyses and updated results are reported...
  18. ncbi Three-weekly docetaxel with prednisone is feasible for Japanese patients with hormone-refractory prostate cancer: a retrospective comparative study with weekly docetaxel alone
    Toru Shimazui
    Department of Urology, Institute of Clinical Medicine, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Ibaraki, Japan
    Jpn J Clin Oncol 37:603-8. 2007
    ..Here, we compare it with the regimen of docetaxel once every 3 weeks (q3w) plus daily prednisone (PSL) based on a TAX 327 trial in order to clarify the efficacy and toxicity of docetaxel regimens in Japan...
  19. ncbi Efficacy of S-1 in patients with castration-resistant prostate cancer: a phase II study
    Hideyuki Akaza
    Department of Urology and Andrology, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Japan
    Oncology 78:323-8. 2010
    ..The primary endpoint was prostate-specific antigen (PSA) response...
  20. ncbi FOXO1 and TCF7L2 genes involved in metastasis and poor prognosis in clear cell renal cell carcinoma
    Takahiro Kojima
    Department of Urology, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Japan
    Genes Chromosomes Cancer 49:379-89. 2010
    ..We conclude that FOXO1 and TCF7L2 are involved in metastasis and that molecules in these signaling pathways may be targets for diagnostic procedures and therapies for CRCC...
  21. ncbi Completion and toxicity of induction chemotherapy for metastatic testicular cancer: an updated evaluation of Japanese patients
    Koji Kawai
    Department of Urology, University of Tsukuba, Ibaraki 305, Japan
    Jpn J Clin Oncol 36:425-31. 2006
    ..Therefore, we re-evaluated the completion and toxicity of BEP combined with modern supportive care...
  22. ncbi Comparisons of percent equol producers between prostate cancer patients and controls: case-controlled studies of isoflavones in Japanese, Korean and American residents
    Hideyuki Akaza
    Department of Urology, University of Tsukuba, Tsukuba, Ibaraki, Japan
    Jpn J Clin Oncol 34:86-9. 2004
    ..The results also suggest that a diet based on soybean isoflavones will be useful in preventing prostate cancer...
  23. ncbi Background Variables for the Patients with Invasive Bladder Cancer Suitable for Bladder-preserving Therapy
    Naoto Miyanaga
    Department of Urology, Institute of Clinical Medicine, University of Tsukuba, 1 1 1 Tennoudai, Tsukuba City, Ibaraki 305 8575, Japan
    Jpn J Clin Oncol 37:852-7. 2007
    ..The present study was undertaken to identify the patients suitable for bladder preservation by analysis of our data...
  24. ncbi Successful outcomes using combination therapy of interleukin-2 and interferon-alpha for renal cell carcinoma patients with lung metastasis
    Hideyuki Akaza
    Department of Urology and Andrology, Graduate School of Comprehensive Human Science, University of Tsukuba, Tsukuba, Ibaragi, Japan
    Jpn J Clin Oncol 40:684-9. 2010
    ..In this paper, the clinical response to our combination therapy is reported...
  25. ncbi Weekly administration of docetaxel in patients with hormone-refractory prostate cancer: a pilot study on Japanese patients
    Takahiro Kojima
    Department of Urology, Institute of Clinical Medicine, University of Tsukuba, 2 1 1 Amakubo, Tsukuba City, Ibaraki 305 8576, Japan
    Jpn J Clin Oncol 34:137-41. 2004
    ..The purpose of this study was the investigation of the efficacy of docetaxel for Japanese patients with HRPC...
  26. ncbi Association of HER-2 polymorphism with Japanese sporadic prostate cancer susceptibility
    Akira Yokomizo
    Department of Urology, Graduate School of Medical Science, Kyushu University, Fukuoka 812 8582, Japan
    Prostate 62:49-53. 2005
    ..To determine the association of the HER-2 gene with Japanese sporadic Pca, we analyzed the frequency of codon 655 (A/G, isoleucine, or valine) in case and control group...
  27. ncbi The level of cadherin-6 mRNA in peripheral blood is associated with the site of metastasis and with the subsequent occurrence of metastases in renal cell carcinoma
    Toru Shimazui
    Department of Urology, Institute of Clinical Medicine, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba City, Ibaraki, Japan
    Cancer 101:963-8. 2004
    ....
  28. ncbi An early phase II trial of S-1 in Japanese patients with cytokine-refractory metastatic renal cell carcinoma
    Seiji Naito
    Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
    Cancer Chemother Pharmacol 66:1065-70. 2010
    ..4:1. The aim of this trial was to investigate the efficacy and safety of S-1 in Japanese patients with cytokine-refractory metastatic renal cell carcinoma (RCC)...
  29. ncbi A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety
    Hirotsugu Uemura
    Department of Urology, University of Tsukuba, Graduate School of Comprehensive Human Sciences, Tsukuba 305 8576, Japan
    Jpn J Clin Oncol 40:194-202. 2010
    ..This study aims to assess the efficacy and safety of sunitinib in Japanese patients with metastatic renal cell carcinoma (RCC)...
  30. ncbi Superior anti-tumor efficacy of bicalutamide 80 mg in combination with a luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist monotherapy as first-line treatment for advanced prostate cancer: interim results of a randomized study in Ja
    Hideyuki Akaza
    Department of Urology, Institute of Clinical Medicine, University of Tsukuba, Tsukuba City, Ibaraki, Japan
    Jpn J Clin Oncol 34:20-8. 2004
    ..To evaluate bicalutamide (Casodex) 80 mg as a component of maximum androgen blockade (MAB) in Japanese patients with previously untreated advanced prostate cancer...
  31. ncbi Lectin-reactive alpha-fetoprotein as a marker for testicular tumor activity
    Koji Kawai
    University of Tsukuba, Institute of Clinical Medicine, Department of Urology, Tsukuba, Ibaraki, Japan
    Int J Urol 12:284-9. 2005
    ..In the present study, we used the subfraction profile of LCA-binding AFP to diagnose and monitor testicular tumor activity...
  32. ncbi Negative impact of metabolic syndrome on the responsiveness to sildenafil in Japanese men
    Takahiro Suetomi
    Department of Urology, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Japan
    J Sex Med 5:1443-50. 2008
    ..Several recent studies suggested that the prevalence of erectile dysfunction (ED) was higher in men with metabolic syndrome (MS)...
  33. ncbi A case of metastatic testicular cancer complicated by pulmonary hemorrhage due to choriocarcinoma syndrome
    Shuya Kandori
    Department of Urology, Institute of Clinical Medicine, University of Tsukuba Graduate School of Comprehensive Human Sciences, 1 1 1 Tennodai, Tsukuba, Ibaraki 305, Japan
    Int J Clin Oncol 15:611-4. 2010
    ....
  34. ncbi [Neoadjuvant chemotherapy in muscle-invasive bladder cancer]
    Naoto Miyanaga
    Dept of Urology, Institute of Clinical Medicine, University of Tsukuba, Ibaraki, Japan
    Gan To Kagaku Ryoho 34:1745-9. 2007
    ..Bladder preservation in selected patients on the basis of response to neoadjuvant chemotherapy is a feasible approach. The goal now must be to find more effective drugs and to better predict the individual response to therapy...
  35. ncbi The case for androgen deprivation as primary therapy for early stage disease: results from J-CaP and CaPSURE
    Hideyuki Akaza
    Department of Urology, Institute of Clinical Medicine, University of Tsukuba, Tennodai 1 1 1, Tsukuba, Ibaraki 305 8578, Japan
    J Urol 176:S47-9. 2006
    ....
  36. ncbi Bladder cancer develops 6 years earlier in current smokers: analysis of bladder cancer registry data collected by the cancer registration committee of the Japanese Urological Association
    Shiro Hinotsu
    Urology and Andrology, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Ibaraki, Japan
    Int J Urol 16:64-9. 2009
    ..The present study was undertaken to examine the relationships between smoking history of bladder cancer patients and the age of onset of bladder cancer and tumor characteristics...
  37. ncbi Low expression of microphthalmia-associated transcription factor, a potential molecular target for interferon-alpha susceptibility, is associated with metastasis in renal cell carcinoma
    Toru Shimazui
    Department of Urology, Institute of Clinical Medicine, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Japan
    Cancer Sci 100:1714-8. 2009
    ..Quantification of MITF mRNA expression might be clinically useful to predict metastasis and survival of patients with RCC...
  38. ncbi The limited efficacy of methotrexate, actinomycin D and cisplatin (MAP) for patients with advanced testicular cancer
    Jun Miyazaki
    Department of Urology, Institute of Clinical Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan
    Jpn J Clin Oncol 33:391-5. 2003
    ..Combination chemotherapy of methotrexate, actinomycin D and cisplatin (MAP) is reported to be effective against gestational choriocarcinoma...
  39. ncbi Does tumor size or microvascular invasion affect prognosis in patients with renal cell carcinoma?
    Tomoaki Miyagawa
    Department of Urology, Kitaibaraki Municipal General Hospital, Kitaibaraki, Ibaraki, Japan
    Jpn J Clin Oncol 37:197-200. 2007
    ..We retrospectively evaluated the effects of tumor size and microvascular tumor invasion on the clinical outcomes of patients who had undergone radical nephrectomy for renal cell carcinoma (RCC)...
  40. ncbi Gleason score correlation between biopsy and prostatectomy specimens and prediction of high-grade Gleason patterns: significance of central pathologic review
    Kentaro Kuroiwa
    Department of Urology, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan
    Urology 77:407-11. 2011
    ..A discrepancy in the GS between the biopsy and RP specimens has been reported...
  41. ncbi Efficacy of primary hormone therapy for localized or locally advanced prostate cancer: results of a 10-year follow-up
    Hideyuki Akaza
    Department of Urology, Institute of Clinical Medicine, University of Tsukuba, Tsukuba, Japan
    BJU Int 98:573-9. 2006
    ....
  42. ncbi Characteristics of patients with prostate cancer who have initially been treated by hormone therapy in Japan: J-CaP surveillance
    Hideyuki Akaza
    Department of Urology, University of Tsukuba, Tsukuba, Ibaraki, Japan
    Jpn J Clin Oncol 34:329-36. 2004
    ..Hormone therapy for prostate cancer has empirically prevailed in Japan. We planned to evaluate the trends and outcome of hormone therapy for establishing an adequate guideline...
  43. ncbi Proton beam therapy for invasive bladder cancer: a prospective study of bladder-preserving therapy with combined radiotherapy and intra-arterial chemotherapy
    Masaharu Hata
    Proton Medical Research Center, University of Tsukuba, Tsukuba, Ibaraki, Japan
    Int J Radiat Oncol Biol Phys 64:1371-9. 2006
    ..To present outcomes of bladder-preserving therapy with proton beam irradiation in patients with invasive bladder cancer...
  44. ncbi Validation of Partin tables and development of a preoperative nomogram for Japanese patients with clinically localized prostate cancer using 2005 International Society of Urological Pathology consensus on Gleason grading: data from the Clinicopathological
    Seiji Naito
    Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
    J Urol 180:904-9; discussion 909-10. 2008
    ..We validated the 2001 Partin tables and developed an original nomogram for Japanese patients using the 2005 International Society of Urological Pathology consensus on Gleason grading...
  45. ncbi Pattern of intravesical recurrence after surgical treatment for urothelial cancer of the upper urinary tract: a single institutional retrospective long-term follow-up study
    Ei Ichiro Takaoka
    Department of Urology, Institute of Clinical Medicine University of Tsukuba, Tsukuba, Ibaraki, Japan
    Int J Urol 17:623-8. 2010
    ..To estimate the risk of intravesical recurrence in patients with primary urothelial cancer of the upper urinary tract...
  46. ncbi Survival of metastatic germ cell cancer patients assessed by international germ cell consensus classification in Japan
    Ichiro Shintaku
    Department of Urology, Tohoku University Graduate School of Medicine, 1 1 Seiryo machi, Aoba ku, Sendai, Miyagi 980 8574, Japan
    Jpn J Clin Oncol 38:281-7. 2008
    ..Since the IGCC classification was based on patients treated between 1975 and 1990, we aimed to investigate whether survival has improved for more recently treated Japanese patients...
  47. ncbi The liposome-incorporating cell wall skeleton of Mycobacterium bovis bacillus Calmette-Guéin can directly enhance the susceptibility of cancer cells to lymphokine-activated killer cells through up-regulation of natural-killer group 2, member D ligands
    Jun Miyazaki
    Graduate School of Comprehensive Human Sciences, Department of Urology, University of Tsukuba, Ibaraki, Japan
    BJU Int 108:1520-6. 2011
    ....
  48. ncbi The therapeutic effects of R8-liposome-BCG-CWS on BBN-induced rat urinary bladder carcinoma
    Jun Miyazaki
    Graduate School of Comprehensive Human Sciences, Department of Urology, University of Tsukuba, Tsukuba, Ibaraki, 3058575 Japan
    Anticancer Res 31:2065-71. 2011
    ..We investigated the suppressive effect of liposome-incorporating cell wall skeleton (BCG-CWS) on N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN)-induced urinary bladder carcinogenesis in rats...
  49. ncbi Nrf2 and p53 cooperatively protect against BBN-induced urinary bladder carcinogenesis
    Katsuyuki Iida
    Department of Urology, Institute of Clinical Medicine, University of Tsukuba, Tennoudai 1 1 1, Tsukuba, Ibaraki 305 8577, Japan
    Carcinogenesis 28:2398-403. 2007
    ..These results thus reveal potential interactions between p53 and Nrf2 and their gene batteries, and indicate that both factors cooperatively contribute to tumor prevention...
  50. ncbi The eighth Asia cancer forum: seeking to advance the outcomes of the UN summit: 'global health as the key to a new paradigm in cancer research'
    Norie Kawahara
    Department of Strategic Investigation on Comprehensive Cancer Network, Research, Center for Advanced Science and Technology RCAST, 4 6 1 Komaba, Meguro ku, Tokyo 153 8904, Japan
    Jpn J Clin Oncol 42:1222-31. 2012
    ....
  51. ncbi Higher consumption of green tea may enhance equol production
    Naoto Miyanaga
    Department of Urology, Post Graduate University of Tsukuba, Ibaraki, 305 8575, Japan
    Asian Pac J Cancer Prev 4:297-301. 2003
    ..In the present study, we examined relationships between type of food intake and the capacity for equol production in Japanese subjects...
  52. ncbi A low-dose combination therapy of interleukin-2 and interferon-alpha is effective for lung metastasis of renal cell carcinoma: a multicenter open study
    Hideyuki Akaza
    Department of Urology, Institute of Clinical Medicine, University of Tsukuba, 2 1 1 Amakubo, Tsukuba 305 0005, Japan
    Int J Clin Oncol 11:434-40. 2006
    ..Efficacy and safety at this dose was evaluated (phase 2)...
  53. ncbi Persistence of prostatic intraepithelial neoplasia after effective chemoprevention of microscopic prostate cancer with antiandrogen in a rat model
    Atsushi Yamauchi
    Department of Urology, Institute of Clinical Medicine, University of Tsukuba, Tsukuba City, Ibaraki, Japan
    J Urol 175:348-52. 2006
    ..In the current study we determined whether antiandrogen would promote or suppress the prostate carcinogenesis when administration was begun at a later period of carcinogenesis...
  54. ncbi Prospective randomized trial of natural interferon-alpha versus natural interferon-alpha plus cimetidine in advanced renal cell carcinoma with pulmonary metastasis
    Toshiaki Kinouchi
    Department of Urology, Osaka Medical Center for Cancer and Cardiovascular Diseases, 1 3 3 Nakamichi, Higashinari ku, Osaka, 537 8511, Japan
    J Cancer Res Clin Oncol 132:499-504. 2006
    ....
  55. ncbi Current status of chemotherapy in risk-adapted management for metastatic testicular germ cell cancer
    Koji Kawai
    Department of Urology, Institute of Clinical Medicine, University of Tsukuba Graduate School of Comprehensive Human Sciences, Tsukuba, Ibaraki, Japan
    Cancer Sci 101:22-8. 2010
    ..Along with the progress in chemotherapy, the risk-adapted management at experienced hospitals seems to be responsible for the recent progress in treatment outcome...
  56. ncbi The 5th Conference on Asian Trends in Prostate Cancer Hormone Therapy
    Hideyuki Akaza
    Institute of Clinical Medicine, University of Tsukuba, Japan
    Asian Pac J Cancer Prev 8:3-12. 2007
    ..Prednisone and dexamethasone are used for secondary hormonal therapy. External beam radiotherapy, radioisotopic drugs such as strontium 89, and bisphosphonates are common choices to control bone pain...
  57. ncbi The 2nd conference on Asian trends in prostate cancer hormone therapy
    Hideyuki Akaza
    Department of Urology, Institute of Clinical Medicine, University of Tsukuba, Ibaraki 305-8576, Japan
    Gan To Kagaku Ryoho 30:1533-42. 2003
    ..quot; This session included 2 lively discussions, on whether Asian physicians can apply Western clinical data to Asian patients, and the need for Asian clinical data and developing clinical trials in the region, respectively...
  58. ncbi Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a Japanese perspective--the effect of primary androgen deprivation therapy on stage C prostate cancer
    Hideyuki Akaza
    Department of Urology, University of Tsukuba, Ibaraki, Japan
    BJU Int 99:10-2; discussion 17-8. 2007
    ....
  59. ncbi Long-term results of first-line sequential high-dose carboplatin, etoposide and ifosfamide chemotherapy with peripheral blood stem cell support for patients with advanced testicular germ cell tumor
    Tsuneharu Miki
    Department of Urology, Kyoto Prefectural University of Medicine, Graduate School of Medical Sciences, Kyoto, Japan
    Int J Urol 14:54-9. 2007
    ..High-dose carboplatin, etoposide, ifosfamide chemotherapy followed by autologous peripheral blood stem cell transplantation (PBSCT) was investigated as first-line chemotherapy in patients with advanced testicular GCT...
  60. ncbi Prostate cancer chemoprevention study: an investigative randomized control study using purified isoflavones in men with rising prostate-specific antigen
    Naoto Miyanaga
    Department of Urology and Andrology, Graduate School of Comprehensive Human Science, University of Tsukuba, Tsukuba, Japan
    Cancer Sci 103:125-30. 2012
    ..Registered with the UMIN Clinical Trials Registry (UMIN-CTR) for clinical trials in Japan (C000000446)...
  61. ncbi Real-time elastography for the diagnosis of prostate cancer: evaluation of elastographic moving images
    Tomoaki Miyagawa
    Department of Urology, Kitaibaraki Municipal General Hospital, 4 5 15 Ohtsu cho, Kita cho, Kita Ibaraki City, Ibaraki, Japan
    Jpn J Clin Oncol 39:394-8. 2009
    ..Elastography is a technique for detecting the stiffness of tissues. We applied elastography for the diagnosis of prostate cancer and evaluated the usefulness of elastography for prostate biopsy...
  62. ncbi Evidence-based clinical practice guidelines for renal cell carcinoma (Summary--JUA 2007 Edition)
    Tomoaki Fujioka
    Department of Urology, Iwate Medical University School of Medicine, Morioka, Iwate, Japan
    Int J Urol 16:339-53. 2009
    ..An abridged edition of these guidelines can be found on the web pages of the Japan Society of Clinical Oncology and the Medical Information Network Distribution Service...
  63. ncbi Extremely acute exacerbation of interstitial pneumonia after interferon-alpha treatment for metastatic renal cell carcinoma
    Satoshi Ando
    Graduate School of Comprehensive Human Sciences, Institute of Clinical Medicine, Department of Urology, University of Tsukuba, Tsukuba, Ibaraki, Japan
    Int J Clin Oncol 14:171-3. 2009
    ..Urologists should be aware of this complication in the treatment of renal cell carcinoma patients who have a prior history of interstitial pneumonia...
  64. ncbi Sustained prophylactic effect of intravesical bacille Calmette-Guérin for superficial bladder cancer: a smoothed hazard analysis in a randomized prospective study
    Shiro Hinotsu
    Department of Urology, Institute of Clinical Medicine, University of Tsukuba, Ibaraki, Japan
    Urology 67:545-9. 2006
    ..CONCLUSIONS: BCG instillation may prevent tumor recurrence caused by both tumor cell implantation and second primary tumors...
  65. ncbi Endocrine therapy with or without radical prostatectomy for T1b-T3N0M0 prostate cancer
    Yukio Homma
    Department of Urology, University of Tokyo, Tokyo, Japan
    Int J Urol 11:218-24. 2004
    ..We retrospectively compared the 5-year survival rates of T1b-T3N0M0 prostate cancer patients treated either by endocrine therapy plus radical prostatectomy or endocrine therapy alone...
  66. ncbi Cavernous hemangioma mimicking a cystic renal cell carcinoma
    Ei Ichiro Takaoka
    Department of Urology, Institute of Clinical Medicine, 1 1 1 Tennodai, Tsukuba, Ibaragi, 305 8575, Japan
    Int J Clin Oncol 13:166-8. 2008
    ..When we find a renal cyst with a solid component, renal cavernous hemangioma arising from the cyst wall should be considered in the differential diagnosis, and a conservative surgical approach should be considered...
  67. ncbi Tissue elasticity imaging for diagnosis of prostate cancer: a preliminary report
    Naoto Miyanaga
    Department of Urology, Graduate School of Comprehensive Human Sciences, Tsukuba, Japan
    Int J Urol 13:1514-8. 2006
    ..It is expected to become a new diagnostic modality for prostate cancer. The aim of this study was to examine the usefulness of elastography in the diagnosis of prostate cancer...
  68. ncbi Efficacy and safety of gemcitabine monotherapy in patients with transitional cell carcinoma after Cisplatin-containing therapy: a Japanese experience
    Hideyuki Akaza
    Department of Urology, Institute of Clinical Medicine, University of Tsukuba, Tsukuba City, Ibaraki, Japan
    Jpn J Clin Oncol 37:201-6. 2007
    ..However, a second-line therapy is still required for patients with recurrent TCC who discontinued MVAC because of toxicity or have MVAC refractory tumors...
  69. ncbi Clinical parameters that predict histology of postchemotherapy retroperitoneal lymph node mass in testicular cancer
    Mizuki Onozawa
    Department of Urology, Institute of Clinical Medicine, University of Tsukuba, Tsukuba City, Japan
    Int J Urol 11:535-41. 2004
    ..5 cm. CONCLUSIONS: Both postchemotherapy RPLN mass size and pretreatment tumor marker levels are possible predictors for necrosis of the residual mass in testicular cancer patients...
  70. ncbi The impact of real-time tissue elasticity imaging (elastography) on the detection of prostate cancer: clinicopathological analysis
    Masakazu Tsutsumi
    Department of Urology, Hitachi General Hospital, Johnan cho 2 1 1, Hitachi, Ibaraki, 317 0077, Japan
    Int J Clin Oncol 12:250-5. 2007
    ..We evaluated the accuracy and feasibility of real-time elastography for detecting prostate cancer, using prostatectomy specimens...
  71. ncbi Differential profiling analysis of proteins involved in anti-proliferative effect of interferon-alpha on renal cell carcinoma cell lines by protein biochip technology
    Kogenta Nakamura
    Department of Urology, Aichi Medical University School of Medicine, Aichi 480-1195, Japan
    Int J Oncol 28:965-70. 2006
    ..Furthermore, the discovery of a susceptibility and or a inhibitory factor may eventually lead to the development of a novel drug targeting the respective factor for the improvement of anticancer chemotherapy...
  72. ncbi Immunoprotection against murine bladder carcinoma by octaarginine-modified liposomes incorporating cell wall of Mycobacterium bovis bacillus Calmette-Guérin
    Akira Joraku
    Graduate School of Comprehensive Human Sciences, Department of Urology, University of Tsukuba, Tsukuba, Ibaraki, Japan
    BJU Int 103:686-93. 2009
    ....
  73. ncbi Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma
    Hideyuki Akaza
    Department of Urology and Andrology, Graduate School of Comprehensive Human Science, University of Tsukuba, Tsukuba 305 8576, Japan
    Jpn J Clin Oncol 37:755-62. 2007
    ..This phase II study investigated efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma (RCC)...
  74. ncbi Phase III trial of everolimus in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from RECORD-1
    Taiji Tsukamoto
    Sapporo Medical University, Sapporo, Japan
    Jpn J Clin Oncol 41:17-24. 2011
    ..To assess the efficacy and safety of everolimus in Japanese patients with metastatic renal cell carcinoma...
  75. ncbi What should we do to raise awareness on the issue of cancer in the global health agenda?
    Norie Kawahara
    Research Center for Advanced Science and Technology, The University of Tokyo, 4 6 1 Komaba, Meguro ku, Tokyo, 153 8904, Japan
    Jpn J Clin Oncol 40:i82-85. 2010
    ..Based on the challenges and outlook for placing cancer on the global health agenda, we conduct analysis that focuses on top-down mechanisms and bottom-up mechanisms...
  76. ncbi Habitual intake of lactic acid bacteria and risk reduction of bladder cancer
    Yasuo Ohashi
    School of Health Sciences and Nursing, University of Tokyo, Tokyo, Japan
    Urol Int 68:273-80. 2002
    ..So, to assess the preventive effect of the intake of L. casei, widely taken as fermented milk products in Japan, against bladder cancer, we conducted a case-control study...
  77. ncbi The 6th Asia cancer forum: what should we do to place cancer on the global health agenda? Sharing information leads to human security
    Norie Kawahara
    Department of Strategic Investigation on Comprehensive Cancer Network, Research, Center for Advanced Science and Technology RCAST, 4 6 1 Komaba, Meguro ku, Tokyo 153 8904, Japan
    Jpn J Clin Oncol 41:723-9. 2011
    ..It was also noted that in order to create a cancer information network, support would need to be provided to low- and middle-income countries and efforts made to ensure that data are comparable...
  78. ncbi The 7th Asia Cancer Forum: from the perspective of human security, how can we collaborate as Asians in order to place cancer on the global health agenda? How can we fill in the gaps that exist among us?
    Norie Kawahara
    Department of Strategic Investigation on Comprehensive Cancer Network, Research, Center for Advanced Science and Technology RCAST, 4 6 1 Komaba, Meguro ku, Tokyo 153 8904 Japan
    Jpn J Clin Oncol 41:825-31. 2011
    ..Participants concurred that cancer issues are decoupled from the development aid agenda and that cooperation should be advanced on the basis of international cooperation without recourse to governmental development aid...
  79. ncbi [The possibility of S-1 for the treatment of patients with urological cancers]
    Hideyuki Akaza
    Dept. of Urology, Institute of Clinical Medicine, University of Tsukuba, Japan
    Gan To Kagaku Ryoho 33:236-8. 2006
    ..Two phase II trials are being conducted to evaluate the efficacy and safety of S-1 as a single agent therapy for patients with hormone-refractory prostate cancer (HRPC) and renal cell carcinoma (RCC)...
  80. ncbi Laminin expression patterns in human ureteral tissue
    Kazunori Hattori
    Department of Urology, University of Tsukuba, 1 1 1 Tennodai, Tsukuba, Ibaraki 305 8575, Japan
    J Urol 170:2040-3. 2003
    ..In this study we examined the expression patterns of the laminin chains in human ureteral tissue in vitro and in vivo...
  81. ncbi Advanced renal cell carcinoma treated with granulocyte-macrophage colony-stimulating factor gene therapy: a clinical course of the first Japanese experience
    Koji Kawai
    Department of Urology, Institute of Clinical Medicine, University of Tsukuba, Ibaraki, Japan
    Int J Urol 9:462-6. 2002
    ..Careful histological examination by autopsy revealed that the responding mass was infiltrated by CD8 positive dominant T lymphocytes, and did not exhibit vasculitis or any other changes associated with active autoimmune disease...
  82. ncbi Role of complex cadherins in cell-cell adhesion evaluated by spheroid formation in renal cell carcinoma cell lines
    Toru Shimazui
    Department of Urology, Institute of Clinical Medicine, University of Tsukuba, 1 1 1 Tennodai, Tsukuba, Ibaraki 305 8575, Japan
    Oncol Rep 11:357-60. 2004
    ..In conclusion, E-cadherin and cadherin-6 are shown to act in cell-cell adhesion whereas N-cadherin might play a somewhat different role from cell-cell adhesion in RCC cell lines...
  83. ncbi Detection of cadherin-6 mRNA by nested RT-PCR as a potential marker for circulating cancer cells in renal cell carcinoma
    Toru Shimazui
    Department of Urology, Institute of Clinical Medicine, University of Tsukuba, Tsukuba City, Ibaraki 305 8575, Japan
    Int J Oncol 23:1049-54. 2003
    ..Detection of cadherin-6 mRNA in non-metastatic presurgical RCC patients suggests that careful follow-up study is necessary in these patients...
  84. ncbi Intraoperative transesophageal echocardiography for inferior vena caval tumor thrombus in renal cell carcinoma
    Takehiro Oikawa
    Department of Urology, Institute of Clinical Medicine, University of Tsukuba, Tsukuba-city, Ibaraki, Japan
    Int J Urol 11:189-92. 2004
    ....
  85. ncbi Paclitaxel, ifosfamide and cisplatin regimen is feasible for Japanese patients with advanced germ cell cancer
    Koji Kawai
    Institute of Clinical Medicine, Department of Urology, University of Tsukuba, 1 1 1 Tennodai, Tsukuba City, Ibaraki 305, Japan
    Jpn J Clin Oncol 33:127-31. 2003
    ..The purpose of this study was to assess the feasibility of a TIP regimen for Japanese patients with advanced germ cell cancer...
  86. ncbi Is daidzein non-metabolizer a high risk for prostate cancer? A case-controlled study of serum soybean isoflavone concentration
    Hideyuki Akaza
    Department of Urology, Institute of Clinical Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan
    Jpn J Clin Oncol 32:296-300. 2002
    ..However, to date there have been no case-controlled clinical studies carried out to compare the circulating concentrations of isoflavones in prostate cancer patients and control subjects...
  87. ncbi [Significance of current bio- and molecular-markers in urological cancers]
    Toru Shimazui
    Department of Urology, Institute of Clinical Medicine, University of Tsukuba, 1-1-1 Tennoudai, Tsukuba, Ibaraki 305-8575, Japan
    Gan To Kagaku Ryoho 31:1008-14. 2004
    ..In renal cell carcinoma (RCC), unfortunately, no definitive biomarker is available for its diagnosis and monitoring. Thus, we must find new specific bio- and molecular-markers that reflect the biological activity of RCC...
  88. ncbi Trends in primary androgen depletion therapy for patients with localized and locally advanced prostate cancer: Japanese perspective
    Hideyuki Akaza
    Urology and Andrology, Functional and Regulatory Medical Sciences, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Ibaraki, 305 8575, Japan
    Cancer Sci 97:243-7. 2006
    ..The effectiveness of PADT in LAPC, in particular, is worthy of attention. There is a possibility that therapeutic strategies for LPC and LAPC may change dramatically in the near future...
  89. ncbi Expression profile of N-cadherin differs from other classical cadherins as a prognostic marker in renal cell carcinoma
    Toru Shimazui
    Department of Urology, Institute of Clinical Medicine, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Ibaraki 305 8575, Japan
    Oncol Rep 15:1181-4. 2006
    ....
  90. ncbi Effectiveness of Maximal Androgen Blockade (MAB): illusion or reality?
    Hideyuki Akaza
    Department of Urology, Institute of Clinical Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan
    Can J Urol 12:77-80. 2005
    ..Having said that, fundamental research and clinical trials in recent years do indicate that the benefit of MAB is not merely an illusion...
  91. ncbi [Cancer screening]
    Hideyuki Akaza
    Dept. of Urology, University of Tsukuba, Japan
    Gan To Kagaku Ryoho 32:125-34. 2005
    ..This and other initiatives will build on the progress of the past 20 years but it is generally agreed that there is still have a long way to go...
  92. ncbi Enhancement of T cell proliferative response against autologous cancer cells of a metasatic renal cell carcinoma patient after unexplained regression
    Koji Kawai
    Department of Urology, Institute of Clinical Medicine, University of Tsukuba, 1 1 1 Tennodai, Tsukuba, Ibaraki 305, Japan
    Int J Urol 11:1130-2. 2004
    ..To our knowledge, the enhancement of an antitumor immunity secondary to an unexplained regression of RCC has not previously been reported...
  93. ncbi Gene expression profiles correlate with the morphology and metastasis characteristics of renal cell carcinoma cells
    Yoshihiro Ami
    Department of Biochemistry and Molecular Oncology, Comprehensive Human Science, Graduate School, University of Tsukuba, Ibaraki 305-8573, Japan
    Oncol Rep 13:75-80. 2005
    ..The unique profiling pattern of gene expression clearly correlated with cell morphology and metastatic potential. Such profiling might contribute to identifying the genes involved in the clinical characteristics of RCC...
  94. ncbi [Renal cell carcinoma]
    Toru Shimazui
    Dept of Urology, Institute of Clinical Medicine, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Ibaraki, Japan
    Gan To Kagaku Ryoho 31:2073-5. 2004
    ..Animal models have indicated that detection of sentinel nodes in RCC might facilitate a more personalized treatment of LND in RCC...
  95. ncbi Phase I study of autologous tumor vaccines transduced with the GM-CSF gene in four patients with stage IV renal cell cancer in Japan: clinical and immunological findings
    Kenzaburo Tani
    Advanced Clinical Research Center, The Institute of Medical Science, University of Tokyo, Tokyo 108 8639, Japan
    Mol Ther 10:799-816. 2004
    ..Our results suggest that GVAX substantially enhanced the antitumor cellular and humoral immune responses, which might have contributed to the relatively long survival times of our patients in the present study...
  96. ncbi The Influence of handling censored data on estimating progression-free survival in cancer clinical trials (JCOG9913-A)
    Miyuki Niimi
    Japan Clinical Oncology Group Data Center, Cancer Information and Epidemiology Division, National Cancer Center Research Institute, Tokyo, Japan
    Jpn J Clin Oncol 32:19-26. 2002
    ..Progression-free survival (PFS) is a common endpoint in cancer clinical trials. This study was undertaken to assess the impact of data errors and data handling on the statistical estimation of PFS...
  97. ncbi Future prospects for luteinizing hormone-releasing hormone analogues in prostate cancer treatment
    Hideyuki Akaza
    Department of Urology, Institute of Clinical Medicine, University of Tsukuba, Tsukuba, Japan akazah md tsukuba ac jp
    Pharmacology 85:110-20. 2010
    ....
  98. ncbi Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles
    Kenji Tamura
    Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
    Cancer Res 67:5117-25. 2007
    ..Our microarray analysis of HRPC cells should provide useful information to understand the molecular mechanism of HRPC progression and to identify molecular targets for development of HRPC treatment...
  99. ncbi [Urological cancer]
    Naoto Miyanaga
    Dept of Urology, Institute of Clinical Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan
    Gan To Kagaku Ryoho 36:193-8. 2009
    ..Thus, new anticancer drugs such as taxanes and gemcitabine were added to cisplatin-based chemotherapy, and a treatment of urological cancer is progressing...